Farnese, 11/05/2018, 15:00 - 16:30
Comunicazioni 3: Carcinoma della prostata 1 – diagnostica
MODERATORE: FRANCESCO MONTANARI
MODERATORE: FEDERICA MARCHESOTTI
MODREATORE: MARIA CONSIGLIA FERRIERO
IS THERE A NEED FOR STRINGENT PREANALYTICAL OPERATING PROCEDURES FOR FREE PSA AND PHI DETERMINATION? OUR PRELIMINARY EXPERIENCE
Multiparametric MRI for the Naïve biopsy patients after a first step with PHI (prostate health index) score
Complications after random TRUS guidedtransrectal prostate biopsy
Primary transrectal random prostate biopsy: is still actual?
mpMRI/ultrasound fusion-guided prostate biopsy: can we forget random cores?
MRI/US FUSION PROSTATE BIOPSY: OUR EXPERIENCE
Development and external validation of MRI-based nomogram to predict the probability of Prostate Cancer diagnosis with MRI-US fusion biopsy
MRI-based nomogram to predict clinically significant Prostate Cancer on MRI/TRUS fusion prostate biopsy: development and external validation
The rebiopsy of the prostate in the era of multiparametric (mp) magnetic resonance imaging (mp-MRI): saturation technique against target only fusion biopsy
Atypical Adenomatous Hyperplasia (AAH) of the prostate in a case report with previuos diagnosis of ASAP (Atypical Small Acinar Proliferation): a review of the literature
Vascular Hurst index in non-tumoral biopsy cores as potential histopathological parameter to select patients with hidden prostate cancer
ADAR1 is highly expressed in primary prostate cancer and correlated with CD8+ T-lymphocytes density
SERPINB3: a novel histopathological biomarker of prostate cancer aggressiveness